Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio. This panel enables rapid detection of five common bacterial pathogens in outpatient settings, including Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica.

This marks QIAGEN's second FDA clearance in 2025 and sixth regulatory clearance for QIAstat-Dx panels in the past 10 months. The new panel complements the existing QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers both bacterial and viral targets.

The system delivers results in about one hour with minimal hands-on time, using real-time PCR technology. QIAGEN's QIAstat-Dx platform has achieved significant market penetration with over 4,600 instruments placed worldwide through 2024. The company is awaiting U.S. regulatory clearance for its new QIAstat-Dx Rise instrument, capable of processing up to 160 tests daily.

QIAGEN (NYSE: QGEN) has filed a patent infringement lawsuit against bioMérieux (EPA: BIM) in the German Unified Patent Court, specifically concerning European Patent EP 2 276 883 B2 related to its QuantiFERON technology. The legal action aims to protect innovations in the QuantiFERON-TB Gold Plus test, which is important for tuberculosis detection worldwide.

The company recently succeeded in defending another QuantiFERON-related patent against SD Biosensor in Germany. QuantiFERON-TB Gold Plus (QFT-Plus) is endorsed by the WHO and CDC for identifying individuals at risk of developing active TB, offering more reliable and objective results compared to traditional skin tests.

QIAGEN (NYSE: QGEN) has announced the opening of a new data center in Melbourne, Australia, expanding its global bioinformatics infrastructure to eight facilities worldwide. The new center will serve the Australia/Asia-Pacific region, including Australia, New Zealand, New Guinea, and surrounding islands.

The Melbourne facility joins QIAGEN's existing network of data centers in the United States, United Kingdom, Denmark, Turkey, South Korea, Japan, and China. It will provide in-country data hosting services, enabling genomic testing laboratories to comply with Australian privacy and health data regulations while securely managing sensitive data.

QIAGEN Digital Insights currently serves 90,000 users worldwide and has profiled 4 million patient cases over its 25-year history in the industry. The expansion demonstrates QIAGEN's commitment to supporting clinical next-generation sequencing (NGS) testing services and ensuring data security, compliance, and operational excellence globally.

QIAGEN reported solid Q4 2024 performance with net sales of $521 million (+2% actual rates, +4% CER core growth). Q4 highlights include net sales of $525 million CER exceeding the $520 million outlook and adjusted diluted EPS of $0.61 surpassing guidance. The adjusted operating income margin improved to 30.6%, up 2.6 percentage points from Q4 2023.

Key products QIAstat-Dx, QuantiFERON, and QIAcuity maintained double-digit growth. For full-year 2024, the company exceeded sales and adjusted EPS outlook, with free cash flow increasing 63% to $506 million. The 2025 outlook projects about 4% CER sales growth (5% CER core sales growth) and adjusted diluted EPS of at least $2.28 CER, targeting adjusted operating income margin improvement of at least 150 basis points.

The company returned approximately $300 million to shareholders in January through a synthetic share repurchase.

QIAGEN (NYSE: QGEN) has secured a favorable ruling from the German Federal Patent Court in a patent dispute against SD Biosensor, validating a key patent for its QuantiFERON technology. The decision upholds QIAGEN's intellectual property rights for the German portion of European Patent EP 3 421 997, which protects important innovations in tuberculosis detection.

The ruling reinforces QIAGEN's QuantiFERON-TB Gold Plus position as the global standard for latent TB testing. The technology is part of a portfolio of over 120 patents and is recommended by major health organizations including WHO and CDC. The test offers superior accuracy and reliability compared to traditional skin testing methods for identifying individuals at risk of developing active tuberculosis.

QIAGEN has announced details for a synthetic share repurchase plan to return up to $300 million to shareholders, combining a direct capital repayment with a reverse stock split. The plan follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by 2028.

The repurchase terms include consolidating every 36 issued shares into 35 shares, reducing approximately 6.2 million shares from the 223.9 million shares outstanding at end-2024. Shareholders will receive $1.26 per pre-split share. The last trading day for pre-split shares is planned for January 28, 2025, with consolidated shares beginning trading on January 29, 2025, on both NYSE and Frankfurt Stock Exchange under existing ticker symbols.

QIAGEN N.V. (NYSE: QGEN) has announced its schedule for the release of Q4 2024 financial results. The press release will be issued on Wednesday, February 5, after 22:05 Frankfurt time (21:05 London/16:05 New York). A conference call will follow on Thursday, February 6, at 16:00 Frankfurt time (15:00 London/10:00 New York).

Participants can join the conference call through three options: registering for a callback connection, dialing in directly using provided international numbers, or accessing the audio webcast. The conference ID for phone dial-in is 9237018. A replay of the conference call will be made available through a provided webcast link.

QIAGEN (NYSE: QGEN) has announced plans to return up to $300 million to shareholders through a synthetic share repurchase, combining a direct capital repayment with a reverse stock split. This follows a similar $300 million repurchase completed in early 2024, totaling $600 million of the company's commitment to return at least $1 billion to shareholders by the end of 2028 (absent M&A opportunities).

The synthetic repurchase, scheduled for completion in late January 2025, will be executed through a three-step process: increasing the par value of common shares, implementing a reverse stock split, and reducing the par value back to the original level with direct capital repayment to shareholders. This approach aims to deliver faster returns compared to traditional open-market repurchases while enhancing earnings per share (EPS) through reduction in outstanding shares.

QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity Digital PCR system, enabling simultaneous analysis of up to 12 targets from a single biological sample, more than doubling its previous capability of five targets. This upgrade is achieved through the new QIAcuity Software 3.1 and the launch of the QIAcuity High Multiplex Probe PCR Kit, requiring no hardware changes to existing instruments.

The system has shown strong market adoption with over 2,700 cumulative placements by end of 2024 and citations in more than 550 publications. The enhancement makes lab work more efficient by reducing time, reagent consumption, and sample material usage. The platform integrates partitioning, thermocycling, and imaging into a streamlined workflow, reducing processing times from six to two hours.

The QIAcuity platform is available in one-, four-, and eight-plate versions to accommodate different laboratory sizes and throughput requirements. The technology is particularly valuable for applications in translational research, microbiome analysis, pathogen detection, and cell and gene therapy development.